Use of B-type natriuretic peptide in the risk stratification of community-acquired pneumonia

Journal of Internal Medicine

Volumn 264, Issue 2, 2008, Pages 166-176

  Christ Crain, M ^a   Breidthardt, T ^a   Stolz, D ^a   Zobrist, K ^a   Bingisser, R ^a   Miedinger, D ^a   Leuppi, J ^a   Tamm, M ^a   Mueller, B ^a   Mueller, C ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Biomarker; Mortality; Pneumonia

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; GYRASE INHIBITOR; MACROLIDE; PROCALCITONIN;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; PNEUMONIA SEVERITY INDEX; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT FAILURE;

AGED; AREA UNDER CURVE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CALCITONIN; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKOCYTE COUNT; MALE; NATRIURETIC PEPTIDE, BRAIN; PNEUMONIA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN PRECURSORS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; SWITZERLAND;

EID: 44649099808     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2008.01934.x     Document Type: Article

References (35)

1. Niederman MS. Guidelines for the management of community-acquired pneumonia. Current recommendations and antibiotic selection issues. Med Clin North Am 2001 85 : 1493 509.
2. Mortensen EM, Coley CM, Singer DE et al. Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med 2002 162 : 1059 64.
3. Fine MJ, Smith MA, Carson CA et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996 275 : 134 41.
4. Kaplan V, Angus DC, Griffin MF, Clermont G, Scott Watson R, Linde-Zwirble WT. Hospitalized community-acquired pneumonia in the elderly: age- and sex-related patterns of care and outcome in the United States. Am J Respir Crit Care Med 2002 165 : 766 72.
5. Brueckmann M, Huhle G, Lang S et al. Prognostic value of plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis. Circulation 2005 112 : 527 34.
6. Morgenthaler NG, Struck J, Christ-Crain M, Bergmann A, Muller B. Pro-atrial natriuretic peptide is a prognostic marker in sepsis, similar to the APACHE II score: an observational study. Crit Care 2005 9 : R37 45.
7. Goto T, Takase H, Toriyama T et al. Increased circulating levels of natriuretic peptides predict future cardiac event in patients with chronic hemodialysis. Nephron 2002 92 : 610 5.
8. McCullough PA, Duc P, Omland T et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis 2003 41 : 571 9.
9. Mueller C, Scholer A, Laule-Kilian K et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004 350 : 647 54.
10. Breidthardt T, Laule K, Strohmeyer AH et al. Medical and economic long-term effects of B-type natriuretic peptide testing in patients with acute dyspnea. Clin Chem 2007 53 : 1415 22.
11. Weinfeld MS, Chertow GM, Stevenson LW. Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure. Am Heart J 1999 138 : 285 90.
12. Mueller C, Laule-Kilian K, Scholer A, Perruchoud AP. B-type natriuretic peptide for risk stratification in community-acquired pneumonia. J Intern Med 2005 258 : 391 3.
13. Christ-Crain M, Stolz D, Bingisser R et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006 174 : 84 93.
14. Fine MJ, Auble TE, Yealy DM et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997 336 : 243 50.
15. Cheng V, Kazanagra R, Garcia A et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 2001 37 : 386 91.
16. Cabanes L, Richaud-Thiriez B, Fulla Y et al. Brain natriuretic peptide blood levels in the differential diagnosis of dyspnea. Chest 2001 120 : 2047 50.
17. Harbarth S, Holeckova K, Froidevaux C et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 2001 164 : 396 402.
18. Muller B, Suess E, Schuetz P et al. Circulating levels of pro-atrial natriuretic peptide in lower respiratory tract infections. J Intern Med 2006 260 : 568 76.
19. Christ-Crain M, Morgenthaler NG, Stolz D et al. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397]. Crit Care 2006 10 : R96.
20. Mueller C, Laule-Kilian K, Schindler C et al. Cost-effectiveness of B-type natriuretic peptide testing in patients with acute dyspnea. Arch Intern Med 2006 166 : 1081 7.
21. Ando T, Ogawa K, Yamaki K, Hara M, Takagi K. Plasma concentrations of atrial, brain, and C-type natriuretic peptides and endothelin-1 in patients with chronic respiratory diseases. Chest 1996 110 : 462 8.
22. Hopkins WE, Chen Z, Fukagawa NK, Hall C, Knot HJ, LeWinter MM. Increased atrial and brain natriuretic peptides in adults with cyanotic congenital heart disease: enhanced understanding of the relationship between hypoxia and natriuretic peptide secretion. Circulation 2004 109 : 2872 7.
23. Yap LB, Mukerjee D, Timms PM, Ashrafian H, Coghlan JG. Natriuretic peptides, respiratory disease, and the right heart. Chest 2004 126 : 1330 6.
24. Shor R, Rozenman Y, Bolshinsky A et al. BNP in septic patients without systolic myocardial dysfunction. Eur J Intern Med 2006 17 : 536 40.
25. Ma KK, Ogawa T, de Bold AJ. Selective upregulation of cardiac brain natriuretic peptide at the transcriptional and translational levels by pro-inflammatory cytokines and by conditioned medium derived from mixed lymphocyte reactions via p38 MAP kinase. J Mol Cell Cardiol 2004 36 : 505 13.
26. Tomaru Ki K, Arai M, Yokoyama T et al. Transcriptional activation of the BNP gene by lipopolysaccharide is mediated through GATA elements in neonatal rat cardiac myocytes. J Mol Cell Cardiol 2002 34 : 649 59.
27. Lim WS, van der Eerden MM, Laing R et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003 58 : 377 82.
28. Aronsky D, Haug PJ. Assessing the quality of clinical data in a computer-based record for calculating the pneumonia severity index. J Am Med Inform Assoc 2000 7 : 55 65.
29. Naito T, Suda T, Yasuda K et al. A validation and potential modification of the pneumonia severity index in elderly patients with community-acquired pneumonia. J Am Geriatr Soc 2006 54 : 1212 9.
30. Ewig S, de Roux A, Bauer T et al. Validation of predictive rules and indices of severity for community acquired pneumonia. Thorax 2004 59 : 421 7.
31. Hedlund J, Hansson LO. Procalcitonin and C-reactive protein levels in community-acquired pneumonia: correlation with etiology and prognosis. Infection 2000 28 : 68 73.
32. Almirall J, Bolibar I, Toran P et al. Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest 2004 125 : 1335 42.
33. Smith RP, Lipworth BJ, Cree IA, Spiers EM, Winter JH. C-reactive protein. A clinical marker in community-acquired pneumonia. Chest 1995 108 : 1288 91.
34. Kerttula Y, Leinonen M, Koskela M, Makela PH. The aetiology of pneumonia. Application of bacterial serology and basic laboratory methods. J Infect 1987 14 : 21 30.
35. Christ-Crain M, Jaccard-Stolz D, Bingisser R et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004 363 : 600 7.